{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:11:14Z","timestamp":1779088274857,"version":"3.51.4"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: Administration of SGLT2 inhibitors leads to a reduction in the dosage of loop diuretics in heart failure (HF) patients; however, it is unclear in what patients the dosage can be reduced. We investigated the factors related to the reduction in loop diuretics in patients who have started receiving dapagliflozin, an SGLT2 inhibitor. Methods: In total, 126 consecutive patients with HF who received dapagliflozin for HF at our institution between December 2020 and March 2022 were enrolled. We investigated the change in the dosage of diuretics at the time of dapagliflozin administration and after 6 months and evaluated factors at the time of dapagliflozin initiation that were associated with the dosage of loop diuretic reduction. Results: The median of loop diuretics dosage (oral furosemide equivalent) at the time of dapagliflozin administration was 20 mg\/day (the mean dosage; 29.5 \u00b1 26.5 mg\/day), and after 6 months it decreased to 10 mg\/day (the mean dosage; 14.5 \u00b1 15.9 mg\/day) (p &lt; 0.001). Multivariate analysis showed that the three factors of in-hospital start of dapagliflozin, % patients on \u03b2-blockers, and the dosage of loop diuretics independently predicted the reduction in loop diuretic dosage. Even in analyses excluding patients who initiated dapagliflozin during hospitalization, loop diuretic dosage independently predicted loop diuretic reduction in multivariate analysis. The receiver operating characteristic curve for predicting reduced loop diuretic showed that the cut-off value for loop diuretic at the time of administration of dapagliflozin was 20 mg\/day of oral furosemide equivalent. Conclusions: The dosage of loop diuretic used when dapagliflozin was started is a factor that predicts a subsequent reduction in the dose of loop diuretics.<\/jats:p>","DOI":"10.3390\/jpm15030099","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:41:51Z","timestamp":1741066911000},"page":"99","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combination of SGLT2 Inhibitors and Loop Diuretics in the Treatment of Heart Failure"],"prefix":"10.3390","volume":"15","author":[{"given":"Yoshiki","family":"Murakami","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Graduate School of Medicine, Tokyo 1438541, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-5409","authenticated-orcid":false,"given":"Shunsuke","family":"Kiuchi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Graduate School of Medicine, Tokyo 1438541, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Hisatake","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Graduate School of Medicine, Tokyo 1438541, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Graduate School of Medicine, Tokyo 1438541, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"ref_1","first-page":"e67","article-title":"American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1253\/circj.72.489","article-title":"Impending epidemic: Future projection of heart failure in Japan to the year 2055","volume":"72","author":"Okura","year":"2008","journal-title":"Circ. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1253\/circj.CJ-20-0947","article-title":"JROADHF Investigators. Clinical Characteristics and Outcomes of Hospitalized Patients with Heart Failure from the Large-Scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF)","volume":"85","author":"Ide","year":"2021","journal-title":"Circ. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1253\/circrep.CR-22-0118","article-title":"Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Leads to a Shorter Hospital Stay in Patients with Acute Decompensated Heart Failure","volume":"5","author":"Matsukawa","year":"2023","journal-title":"Circ. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.36628\/ijhf.2022.0009","article-title":"Effects of Empagliflozin on Diuretics Reduction in Outpatient Heart Failure Patients","volume":"4","author":"Kim","year":"2022","journal-title":"Int. J. Heart Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJM197112232852601","article-title":"The natural history of congestive heart failure: The Framingham study","volume":"285","author":"McKee","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"ref_13","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1253\/circj.CJ-21-0431","article-title":"Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS\/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0894-7317(89)80014-8","article-title":"Recommendations for quantitation of the left ventricle by two-dimensional echocardiography","volume":"2","author":"Schiller","year":"1989","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","article-title":"Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial","volume":"8","author":"Butler","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40261-022-01226-7","article-title":"CHAnges in Diuretic Medication Prescribing and Surrogate Laboratory Parameters After Initiating EmpagliflOziN in Veterans (CHAMPION Cohort Study)","volume":"43","author":"Patil","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/eurheartj\/ehi890","article-title":"Heart failure, chronic diuretic use, and increase in mortality and hospitalization: An observational study using propensity score methods","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10741-018-9735-7","article-title":"Loop diuretics in chronic heart failure: How to manage congestion?","volume":"24","author":"Knackstedt","year":"2019","journal-title":"Heart Fail. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ejheart.2007.07.011","article-title":"Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE Tria","volume":"9","author":"Hasselblad","year":"2007","journal-title":"Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/eurheartj\/ehz554","article-title":"Short term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy","volume":"40","author":"Rohde","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: A prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/nep.13552","article-title":"Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan","volume":"24","author":"Ohara","year":"2019","journal-title":"Nephrology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s00380-020-01768-w","article-title":"Glucose-dependent diuresis in relation to improvements in renal-tubular markers of sodium-glucose cotransporter-2 inhibitors in hospitalized heart failure patients with diabetes","volume":"36","author":"Ikeda","year":"2021","journal-title":"Heart Vessels."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jjcc.2020.03.009","article-title":"Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients","volume":"76","author":"Nakagawa","year":"2020","journal-title":"J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/hc1102.105264","article-title":"BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1253\/circrep.CR-20-0041","article-title":"Empagliflozin Administration Can Decrease the Dose of Loop Diuretics and Prevent the Exacerbation of Renal Tubular Injury in Patients with Compensated Heart Failure Complicated by Diabetes","volume":"2","author":"Shirakabe","year":"2020","journal-title":"Circ. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2967\/jnumed.115.156406","article-title":"123I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: The ADMIRE-HFX Study","volume":"56","author":"Narula","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5582\/ddt.2017.01069","article-title":"Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report","volume":"12","author":"Kiuchi","year":"2018","journal-title":"Drug Discov. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jjcc.2021.11.012","article-title":"Management of hypertension associated with cardiovascular failure","volume":"79","author":"Kiuchi","year":"2022","journal-title":"J. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jchf.2017.08.015","article-title":"Reverse J-Curve Relationship Between On-Treatment Blood Pressure and Mortality in Patients with Heart Failure","volume":"5","author":"Lee","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12933-022-01574-w","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: A systematic review and meta-analysis","volume":"21","author":"Li","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/ajh\/hpaa073","article-title":"Empagliflozin for Patients with Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial","volume":"33","author":"Ferreira","year":"2020","journal-title":"Am. J. Hypertens."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kim, H.J., and Jo, S.H. (2024). Effect of low blood pressure on prognosis of acute heart failure. Sci. Rep., 4.","DOI":"10.1038\/s41598-024-66219-2"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchf.2022.09.002","article-title":"Blood Pressure and Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: DELIVER","volume":"11","author":"Selvaraj","year":"2023","journal-title":"JACC Heart Fail."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/3\/99\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:46:26Z","timestamp":1760028386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/3\/99"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jpm15030099"],"URL":"https:\/\/doi.org\/10.3390\/jpm15030099","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]}}}